Pipeline

Today, our drug candidates are focused on treating rare, genetic metabolic diseases, with other major diseases on the horizon.

Synlogic is currently developing medicines that address disease from a base of operation in the gut microbiome using our proprietary approach to creating living Synthetic BioticTM medicines.

  • Our proprietary pipeline includes Synthetic Biotic medicines for the treatment of inborn errors of metabolism (IEM).
  • In collaboration with partners, we will apply our proprietary platform to create innovative Synthetic Biotic medicines for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS.

.

.